President Trump's administration has taken steps toward imposing tariffs on imported medicines by filing a federal notice to investigate whether such imports pose a national security risk. This initiative aims to encourage domestic pharmaceutical production, although experts caution that the move may not lead to the intended outcome, as shifting manufacturing back to the U.S. could be prohibitively expensive and time-consuming. The investigation falls under Section 232, a legal authority previously used for tariffs on cars and lumber. Trump's remarks indicate he intends to implement these tariffs, raising concerns about potential impacts on drug prices and availability.
President Trump's administration initiated an investigation into the national security risks of imported medicines, potentially leading to tariffs that could affect drug prices.
Experts argue that the proposed tariffs on pharmaceuticals are unlikely to bring manufacturing back to the U.S., predicting a costly and lengthy transition.
Collection
[
|
...
]